Several findings suggest that rhACE2 may be a promising drug for people with intolerance to classical renin-angiotensin system (RAS) inhibitors or for diseases with high circulating angiotensin II. Infused rhACE2 has been evaluated in clinical trials for the treatment of acute respiratory distress syndrome.
Matokeo kadhaa yanaonyesha kuwa rhACE2 inaweza kuwa dawa nzuri kwa wale hawawezi kuvumilia vizuizi vya mfumo vya renin-angiotensin (vizuizi vya RAS) au katika magonjwa ambapo angiotensin II inayozunguka imapenda. Mchanganyiko wa rhACE2 umekadiriwa katika majaribio ya kliniki kwa ajili ya matibabu ya matatizo sugu ya upumuaji.